アカルボースとボグリボースの臨床的効果の比較 : アカルボースからボグリボースに処方変更された症例での調査
書誌事項
- タイトル別名
-
- Comparative Evaluation of Clinical Effectiveness of Acarbose and Voglibose Prescribed for Diabetes : In Cases the Prescription was Changed from Acarbose to Voglibose
この論文をさがす
説明
Several years have passed since α-glycosidase inhibitors entered the market as antidiabetics. At present, acarbose and voglibose are the only drugs in this category that are available in Japan. Although several studies have been perfomed on the efficacy and side effects of these drugs, the results are still not uniform. In this study, changes in the laboratory data were investigated in patients treated at our department in whom their medication was changed from acarbose to voglibose. The subjects consisted of 11 outpatients with non-insulin-dependent diabetes mellitus (NIDDM) in whom their medication was changed from 300 mg of acarbose to 0.6 mg of voglibose without any alterations in concomitant drugs. No significant changes were noted in the HbA_<lc>, TG, TC, or HDL-C levels at 16 weeks after the change in medication. In addition, no abnormal data were observed in the GOT, GPT, γ-GTP, ALP, or K levels in patients before or after the change in medication. An interview study showed no remarkable changes in the symptoms except for a decreased frequency of flatus after the change in medication from acarbose to voglibose. The above results suggested that 0.6 mg of voglibose was superior in terms of QOL to 300 mg of acarbose because of a lower incidence of gastrointestinal symptoms, although the hypoglycemic effect was comparable between the 2 drugs. Additional studies should be performed in a larger number of patients to obtain more reliable results.
収録刊行物
-
- 病院薬学
-
病院薬学 26 (1), 87-94, 2000-02-10
日本病院薬剤師会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1543387470086327680
-
- NII論文ID
- 110001166954
-
- NII書誌ID
- AN00002794
-
- 本文言語コード
- ja
-
- データソース種別
-
- NDLデジコレ（旧NII-ELS）
- CiNii Articles